B+
Bull case
30%
Probability
Target price
$4.15
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
APYX
Apyx MedicalBNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$3.25
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$2.10
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-11
Recent news sentiment (30D)
+0.6
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+80.2
Score
AI commentary
Primary operating evidence is constructive, but external coverage is sparse and no sufficient social-sentiment data were supplied. The $2.89 September 10 anchor remains below the $4.16 pre-Q2-release close cited in the prior baseline, suggesting the market has not fully endorsed the improved operating narrative. Post-print analyst revisions, options skew, and current short-interest evidence are unavailable, supporting cautious monitoring rather than a high-conviction bullish conclusion.
RankAlpha Sentiment Codex - 2026-09-11
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-06eventQ2 growth and FY2026 outlook resetHigh impact
Apyx reported Q2 revenue of $13.9 million, up 22%, with Surgical Aesthetics revenue up 28%, and maintained FY2026 revenue guidance of $59-$60 million versus the earlier $57.5-$58.5 million baseline. The results were furnished through an SEC 8-K, while the stored call transcript supplies the operating detail. [#SEC-8K-2026-08-06] [#PR-EARNINGS-2026-08-14]
2026-09-30catalystAYON PowerLipo rolloutHigh impact
Expanded FDA 510(k) clearance and the limited launch of AYON's reusable power-liposuction handpiece create a near-term adoption test. Management cited positive initial surgeon feedback, but evidence of broad placements and utilization remains limited. [#PR-EARNINGS-2026-08-14]
2026-12-31catalystAYON-led recurring-use growthHigh impact
The longer-term thesis requires AYON placements to translate into sustained generator and single-use handpiece demand. Four consecutive quarters of AYON sales and increased domestic handpiece volume are constructive, but durability, margins, and cash-generation remain unproven. [#PR-EARNINGS-2026-08-14] [#10-K-2026-03-10]
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-11 • Updated nightlySource: Internal modelMethodology